Mahmoud Izadi
Community Membership and Engagement Subcommittee
Hamad Bin Khalifa University (HBKU), Doha, Qatar

Research Interest:

My research focuses on understanding genomic instability and the DNA damage response (DDR) within the context of cancer. During my PhD in Genomics and Precision Medicine at Hamad Bin Khalifa University, I looked into the role of tryptophanyl-tRNA synthetase 1 (WARS-1) in genomic stability. Using Caenorhabditis elegans as our model organism, I demonstrated that WARS-1 depletion leads to mitotic cell cycle arrest and chromatin abnormalities, indicative of genomic instability. My findings showed a critical link between elevated tryptophan levels, genomic instability, and DDR activation, providing insights into potential therapeutic targets for precision cancer therapies.

Using a quantitative proteomics approach, I explored the physiological responses of C. elegans to DNA damage induced by cisplatin, a widely used chemotherapy drug. Through this approach, I identified upregulation of several proteins from the Glutathione-S-Transferase (GST) family, which are key players in cellular detoxification of xenobiotics and drugs like cisplatin. The detoxification activity of GSTs contributes to drug resistance, a major challenge in clinical oncology that can undermine the efficacy of chemotherapy regimens over time. Identifying specific GST isoforms upregulated in response to cisplatin provides insights into the molecular mechanisms underlying resistance. Furthermore, these findings highlight opportunities for developing novel therapeutic strategies and personalized medicine approaches, leveraging GST variants to combat chemotherapy resistance and improve patient outcomes.

Currently, as a postdoctoral researcher, I am building on these findings by employing CRISPR-Cas9–mediated genome editing and high-throughput screening to develop humanized models for translational cancer research. I am also contributing to establishing advanced genetic manipulation techniques in C. elegans to expand their applications for ongoing projects in the lab.

In addition to my work with C. elegans, I have developed a profound interest in clinical and translational cancer research, particularly in cancer immunotherapy. My future plans include advancing my expertise in immunology to complement my background in genomic instability and DNA damage response. By integrating these disciplines, I aim to contribute to innovative cancer immunotherapy strategies. My ultimate goal is to translate basic scientific discoveries into therapeutic interventions that improve outcomes for cancer patients, bridging the gap between laboratory research and clinical applications.

As a PhD-trained scientist, you have many career options. What interests you the most? 

I have always envisioned becoming a principal investigator and leading a research group dedicated to innovative scientific discovery while mentoring and training the next generation of scientists. To achieve this vision, I plan to continue postdoctoral research, building expertise in both basic and translational science, and gradually transition into a leadership role in a clinical and translational research setting. My long-term vision is to establish a dynamic laboratory that bridges fundamental discoveries in genomic instability, DNA damage response, and cancer immunotherapy with practical, tangible applications in medicine. This lab would focus not only on advancing scientific knowledge but also on transforming findings into therapeutic solutions, ultimately contributing to improving patient outcomes and fostering a collaborative research environment.

Alongside academia, I am captivated by the entrepreneurial side of science. I aim to collaborate with innovators and entrepreneurs to transform my research findings into practical solutions. My vision is to establish a biotech startup that focuses on developing groundbreaking therapeutic strategies. This endeavor would both accelerate the translation of scientific discoveries into real-world applications and address critical challenges in therapy-resistant cancers. By fostering partnerships with industry leaders, securing venture funding, and applying cutting-edge technologies, I hope to create a platform that bridges the gap between academic innovation and patient-centered solutions. Combining the rigor of academic research with the adaptability of industry offers a transformative pathway to deliver impactful medical advances.

In addition to your research, how do you want to advance the scientific enterprise? 

Science thrives on collaboration and inclusivity, but research is always limited by funding. I aim to advocate for increased funding opportunities and to create programs that connect early career scientists with industry and academic mentors. Additionally, I am committed to enhancing science communication to make research more accessible to the public. By promoting interdisciplinary collaborations and fostering connections across sectors, I hope to take a step towards strengthening the global scientific community.

Mentorship has played a pivotal role in my career, and I am dedicated to paying it forward. I have guided students and peers through academic decisions, fellowship applications, and career transitions. These experiences have deepened my appreciation for the value of supportive academic environments. As a member of the GSA Early Career Scientist (ECS) Community Membership and Engagement (CME) Subcommittee, I contribute to a peer support project designed to provide a safe, inclusive space for researchers to discuss professional challenges, exchange advice, and navigate career milestones. This initiative empowers scientists at all stages by reinforcing a culture of openness and mutual support.

As a leader within the Genetics Society of America, what do you hope to accomplish? 

As part of the Early Career Leadership Program (ECLP) and the ECS CMEt Subcommittee, I aim to strengthen the sense of community among GSA members. By contributing to ongoing projects and proposing initiatives, my goal is to increase member engagement and foster connections that help us grow together.

Through my leadership role, I leverage career development opportunities and apply them in ways that benefit the broader community. I seek to inspire collaboration, amplify the voices of early-career researchers, and help build a more inclusive and supportive environment within GSA.

I have gained invaluable insights and practical tools from the diverse array of workshops, meetings, and courses on leadership and professional development. These experiences have significantly enhanced my leadership capabilities, enabling me to better support students, peers, and early-career researchers in achieving their academic and professional goals. By applying these skills, I aim to cultivate a culture of mentorship, promote collaborative networks, and contribute meaningfully to the scientific community. These competencies will not only guide me as a postdoctoral researcher but will also underpin my journey toward becoming an impactful principal investigator.

Previous leadership experience

During my undergraduate studies, I served as vice president of the Biology Students’ Scientific Association, where I co-founded the Biotechnology Group. Under my leadership, we successfully organized five national congresses focusing on bioinformatics, stem cells, and biotechnology, significantly increasing engagement and participation. I was able to secure funding to establish a bioinformatics center for students. There, with the help of faculty, my team and I organized several workshops on bioinformatics software and using available resources for learning and research. Additionally, we established a student journal on biotechnology—I served on the editorial board and oversaw the publication of original research and review articles by emerging scholars in the field. We also launched a blog dedicated to discussing cutting-edge topics in biology and biotechnology, further enriching the academic community and fostering the exchange of knowledge.

During my time as a research assistant at the Royan Institute in Iran, I contributed to the organization of the annual Royan Twin International Congresses on Stem Cells, serving on the executive and international affairs committees. I also served on the team that established Iran’s third clinical laboratory for SARS-CoV-2 testing, earning a Grade-A certification from the Ministry of Health.

Overall, I  greatly value outreach and education. As part of the “Stem Cells for All” program at the Royan Institute, I traveled to underdeveloped regions of the country to teach students about regenerative medicine and cell therapy. These experiences enriched my skills in communication, collaboration, and teaching, which I continue to apply in my current roles.

, ,
View all posts by Editorial Staff »

Read more in